# Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

> **NCT01523808** · PHASE1 · COMPLETED · sponsor: **ERYtech Pharma** · enrollment: 12 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** GRASPA

## Key facts

- **NCT ID:** NCT01523808
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01523808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01523808, "Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01523808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*